EAM Investors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

EAM Investors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-58,619	Closed	-$2.19M	–	438
2021 Q2	$2.19M	Buy	+58,619	New	+$1.8M	0.34%	107
2020 Q3	–	Sell	-38,983	Closed	-$990K	–	383
2020 Q2	$990K	Sell	38,983 -29,932	-43%	-$645K	0.22%	193
2020 Q1	$1.27M	Sell	68,915 -102,173	-60%	-$1.99M	0.39%	121
2019 Q4	$3.77M	Buy	+171,088	New	+$3.44M	0.83%	15
2019 Q1	–	Sell	-35,673	Closed	-$381K	–	346
2018 Q4	$381K	Sell	35,673 -11,613	-25%	-$153K	0.1%	247
2018 Q3	$722K	Hold	47,286	–	–	0.11%	269
2018 Q2	$579K	Hold	47,286	–	–	0.09%	274
2018 Q1	$452K	Sell	47,286 -17,054	-27%	-$184K	0.08%	279
2017 Q4	$581K	Buy	+64,340	New	+$473K	0.1%	281

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM Investors's DRNA Position: Q3 2021 in Review

EAM Investors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 58,619 shares — an estimated $2.19M sold.

EAM Investors first reported a position in DRNA in Q4 2017 and held it in 9 quarters. The position peaked at $3.77M in Q4 2019. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

EAM Investors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
EAM Investors sold 58,619 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $2.19M.
EAM Investors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 9 quarters.
EAM Investors's Dicerna Pharmaceuticals, Inc. position peaked at $3.77M in Q4 2019.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on EAM Investors's 13F filing for Q3 2021, filed 12 Nov 2021.